ONO Pharmaceutical Co (4528N) Ratios
ONO Pharmaceutical Co Ratios
MX:4528N's free cash flow for Q3 2026 was $31.04B. For the 2026 fiscal year, MX:4528N's free cash flow was decreased by $-1.04B and operating cash flow was $32.08B. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.07 | 2.86 | 3.99 | 2.81 | 4.27 |
| Quick Ratio | 2.56 | 2.51 | 3.52 | 2.44 | 3.63 |
| Cash Ratio | 1.38 | 1.45 | 1.60 | 0.78 | 1.05 |
| Solvency Ratio | 0.28 | 0.43 | 1.27 | 0.97 | 1.27 |
| Operating Cash Flow Ratio | 0.56 | 0.84 | 1.07 | 1.30 | 0.94 |
| Short-Term Operating Cash Flow Coverage | 2.75 | 3.87 | 47.90 | 64.10 | 26.87 |
| Net Current Asset Value | $ 179.26B | $ 218.44B | $ 298.53B | $ 210.48B | $ 203.74B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.14 | 0.11 | 0.01 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.19 | 0.14 | 0.01 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.16 | 0.12 | 0.01 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.12 | 0.08 | 0.01 | 0.01 | 0.01 |
| Financial Leverage Ratio | 1.36 | 1.30 | 1.15 | 1.19 | 1.13 |
| Debt Service Coverage Ratio | 2.49 | 2.86 | 57.66 | 38.58 | 31.02 |
| Interest Coverage Ratio | 38.77 | 29.20 | 712.24 | 155.49 | 131.48 |
| Debt to Market Cap | 0.18 | 0.09 | 0.01 | 0.00 | 0.00 |
| Interest Debt Per Share | 315.77 | 264.92 | 18.94 | 6.88 | 6.50 |
| Net Debt to EBITDA | -0.66 | -0.87 | -0.86 | -0.54 | -0.49 |
| Profitability Margins | |||||
| Gross Profit Margin | 68.90% | 72.52% | 74.71% | 75.39% | 74.12% |
| EBIT Margin | 12.52% | 18.65% | 32.62% | 32.30% | 29.09% |
| EBITDA Margin | 18.05% | 25.97% | 36.23% | 36.20% | 33.99% |
| Operating Profit Margin | 13.02% | 20.03% | 32.45% | 31.75% | 31.80% |
| Pretax Profit Margin | 12.19% | 17.96% | 32.57% | 32.10% | 29.06% |
| Net Profit Margin | 10.28% | 13.53% | 25.46% | 25.21% | 22.28% |
| Continuous Operations Profit Margin | 10.30% | 13.55% | 25.47% | 25.25% | 22.33% |
| Net Income Per EBT | 84.36% | 75.30% | 78.16% | 78.54% | 76.67% |
| EBT Per EBIT | 93.60% | 89.66% | 100.39% | 101.11% | 91.39% |
| Return on Assets (ROA) | 4.70% | 6.31% | 14.01% | 12.77% | 10.89% |
| Return on Equity (ROE) | 6.40% | 8.20% | 16.14% | 15.19% | 12.28% |
| Return on Capital Employed (ROCE) | 6.92% | 10.96% | 20.14% | 18.69% | 17.07% |
| Return on Invested Capital (ROIC) | 5.65% | 7.95% | 15.66% | 14.61% | 13.02% |
| Return on Tangible Assets | 7.02% | 9.55% | 14.94% | 13.86% | 11.94% |
| Earnings Yield | 6.65% | 5.91% | 10.80% | 2.78% | 1.76% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.61 | 3.53 | 3.69 | 3.91 | 3.62 |
| Payables Turnover | 1.69 | 2.25 | 2.09 | 1.65 | 1.88 |
| Inventory Turnover | 2.02 | 2.47 | 2.61 | 2.46 | 2.24 |
| Fixed Asset Turnover | 4.61 | 5.09 | 4.80 | 4.12 | 3.22 |
| Asset Turnover | 0.46 | 0.47 | 0.55 | 0.51 | 0.49 |
| Working Capital Turnover Ratio | 1.58 | 1.69 | 1.89 | 2.04 | 1.96 |
| Cash Conversion Cycle | 66.35 | 89.11 | 64.17 | 20.48 | 70.07 |
| Days of Sales Outstanding | 101.22 | 103.27 | 98.80 | 93.37 | 100.79 |
| Days of Inventory Outstanding | 180.48 | 147.97 | 139.62 | 148.62 | 163.22 |
| Days of Payables Outstanding | 215.35 | 162.13 | 174.25 | 221.51 | 193.95 |
| Operating Cycle | 281.71 | 251.24 | 238.42 | 241.99 | 264.02 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 175.56 | 291.20 | 230.50 | 108.95 | 41.51 |
| Free Cash Flow Per Share | 164.00 | 278.38 | 187.12 | 99.05 | 33.27 |
| Dividend Paid and CapEx Coverage Ratio | 1.92 | 3.14 | 1.91 | 3.61 | 1.55 |
| Capital Expenditure Coverage Ratio | 15.18 | 22.71 | 5.31 | 11.01 | 5.04 |
| Operating Cash Flow Coverage Ratio | 0.56 | 1.13 | 12.49 | 17.41 | 7.02 |
| Operating Cash Flow to Sales Ratio | 0.17 | 0.27 | 0.22 | 0.36 | 0.17 |
| Free Cash Flow Yield | 10.23% | 11.09% | 7.58% | 3.58% | 1.09% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 15.04 | 16.91 | 9.26 | 35.92 | 56.72 |
| Price-to-Sales (P/S) Ratio | 1.55 | 2.29 | 2.36 | 9.06 | 12.64 |
| Price-to-Book (P/B) Ratio | 0.96 | 1.39 | 1.49 | 5.46 | 6.96 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 9.77 | 9.02 | 13.19 | 27.91 | 92.16 |
| Price-to-Operating Cash Flow Ratio | 9.13 | 8.62 | 10.71 | 25.37 | 73.86 |
| Price-to-Earnings Growth (PEG) Ratio | -0.25 | 0.43 | 0.60 | 0.85 | 7.74 |
| Enterprise Value Multiple | 7.91 | 7.94 | 5.64 | 24.48 | 36.69 |
| Enterprise Value | 694.79B | 1.06T | 1.03T | 3.96T | 4.51T |
| EV to EBITDA | 7.91 | 7.94 | 5.64 | 24.48 | 36.69 |
| EV to Sales | 1.43 | 2.06 | 2.04 | 8.86 | 12.47 |
| EV to Free Cash Flow | 9.02 | 8.13 | 11.44 | 27.31 | 90.95 |
| EV to Operating Cash Flow | 8.43 | 7.77 | 9.29 | 24.83 | 72.89 |
| Tangible Book Value Per Share | 930.34 | 1022.46 | 1544.14 | 463.25 | 400.76 |
| Shareholders’ Equity Per Share | 1665.88 | 1810.62 | 1651.71 | 506.38 | 440.35 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.15 | 0.25 | 0.22 | 0.21 | 0.23 |
| Revenue Per Share | 1036.57 | 1097.76 | 1047.05 | 305.24 | 242.60 |
| Net Income Per Share | 106.55 | 148.49 | 266.57 | 76.94 | 54.06 |
| Tax Burden | 0.84 | 0.75 | 0.78 | 0.79 | 0.77 |
| Interest Burden | 0.97 | 0.96 | 1.00 | 0.99 | 1.00 |
| Research & Development to Revenue | 0.31 | 0.29 | 0.22 | 0.21 | 0.21 |
| SG&A to Revenue | 0.25 | 0.24 | 0.15 | 0.15 | 0.17 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.65 | 1.96 | 0.86 | 1.11 | 0.59 |
Currency in JPY